Rpl-003-19 An Open-Label, Multicenter, Phase 1B Study Of Rp1 In Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (Cscc)
Posted Date: Aug 3, 2021
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Oncology
- Type of Study: Drug
The purpose of this study will be to investigate the safety and tolerability of RP1 for the treatment of advanced CSCC in up to 30 evaluable organ transplant recipients. This will include patients with either previous renal or hepatic allograft transplantation and experiencing subsequent documented locally advanced or metastatic CSCC. The experimental arm will receive RP1 administered as an intra-tumoral injection every 2 weeks. Efficacy will be measured by the amount of serious adverse events.
Criteria:
Patients With Histologically Or Cytologically Confirmed Recurrent, Locally Advanced Or Metastatic (To Skin, Soft Tissue Or Lymph Nodes) Cutaneous Squamous Cell Carcinoma, Who Have Progressed Following Local Resection Or One Local (I.E., Topical) Medical T
Keywords:
Phase 1
For More Information:
Uc Cancer Center
5135847698
cancer@uchealth.com